In this study, we tested whether aberrant LRRK2 activity is associated with tau and/or α-synuclein pathology in clinically distinct neurodegenerative diseases by analyzing LRRK2-mediated phosphorylation of Rab12 at amino acid Ser106 (pS106-Rab12). This evidence concerns the gene MAPT and neurodegenerative disease.